AT348115B - Verfahren zur umwandlung eines anti- inflammatorisch wirkenden steroids - Google Patents

Verfahren zur umwandlung eines anti- inflammatorisch wirkenden steroids

Info

Publication number
AT348115B
AT348115B AT352973A AT352973A AT348115B AT 348115 B AT348115 B AT 348115B AT 352973 A AT352973 A AT 352973A AT 352973 A AT352973 A AT 352973A AT 348115 B AT348115 B AT 348115B
Authority
AT
Austria
Prior art keywords
converting
inflammatory steroid
steroid
inflammatory
Prior art date
Application number
AT352973A
Other languages
English (en)
Other versions
ATA352973A (de
Original Assignee
Allen & Hanburys Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10112152&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AT348115(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allen & Hanburys Ltd filed Critical Allen & Hanburys Ltd
Publication of ATA352973A publication Critical patent/ATA352973A/de
Application granted granted Critical
Publication of AT348115B publication Critical patent/AT348115B/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Otolaryngology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pulmonology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT352973A 1972-04-20 1973-04-19 Verfahren zur umwandlung eines anti- inflammatorisch wirkenden steroids AT348115B (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1842172A GB1429184A (en) 1972-04-20 1972-04-20 Physically anti-inflammatory steroids for use in aerosols

Publications (2)

Publication Number Publication Date
ATA352973A ATA352973A (de) 1978-06-15
AT348115B true AT348115B (de) 1979-01-25

Family

ID=10112152

Family Applications (1)

Application Number Title Priority Date Filing Date
AT352973A AT348115B (de) 1972-04-20 1973-04-19 Verfahren zur umwandlung eines anti- inflammatorisch wirkenden steroids

Country Status (23)

Country Link
US (2) US4414209A (de)
JP (1) JPS531814B2 (de)
AR (1) AR196524A1 (de)
AT (1) AT348115B (de)
AU (1) AU471577B2 (de)
BE (1) BE798458A (de)
CA (1) CA994753A (de)
DE (1) DE2320111C2 (de)
DK (1) DK134923B (de)
ES (1) ES413911A1 (de)
FI (1) FI53067C (de)
FR (1) FR2182981B1 (de)
GB (1) GB1429184A (de)
HU (1) HU171209B (de)
IE (1) IE37541B1 (de)
IL (1) IL42038A (de)
LU (1) LU67462A1 (de)
NL (1) NL157797B (de)
NO (1) NO140303C (de)
PH (1) PH13620A (de)
SE (1) SE399642B (de)
YU (1) YU39602B (de)
ZA (1) ZA732713B (de)

Families Citing this family (296)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX3864E (es) * 1975-05-27 1981-08-26 Syntex Corp Un proceso para prepara el compuesto cristalino 6-fluiro-11b 21-dihiroxi-16 17-isopropilidendioxipregna-1 4-dien-3 20-diona
US4933168A (en) * 1975-05-27 1990-06-12 Syntex Pharmaceuticals International Limited Stable, crystalline flunisolide
GB1571629A (en) * 1977-11-30 1980-07-16 Fisons Ltd Pharmaceutical compositions containing beclomethasone dipropionate
IT1121513B (it) * 1979-05-28 1986-04-02 Chiesi Farma Spa Processo per la conversione di umo steroide antiinfiammatorio in una forma suscettibile di essere somministarta come aerosol
ATE3774T1 (de) * 1980-05-02 1983-06-15 Schering Corporation Beclomethason-ester-solvate, verfahren zu ihrer herstellung und herstellung einer formulierung.
FI63672C (fi) * 1980-05-19 1983-08-10 Orion Yhtymae Oy Foerfarande foer framstaellning av en blandning av beklometasondipropionat och triklorfluormetan eller diklordifluormetan
KR890000664B1 (ko) * 1981-10-19 1989-03-22 바리 안소니 뉴우샘 미분된 베클로메타손 디프로피오네이트 일수화물의 제조방법
GB8432063D0 (en) * 1984-12-19 1985-01-30 Riker Laboratories Inc Physically modified steroids
US5962490A (en) * 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5562608A (en) * 1989-08-28 1996-10-08 Biopulmonics, Inc. Apparatus for pulmonary delivery of drugs with simultaneous liquid lavage and ventilation
US5736509A (en) * 1990-12-14 1998-04-07 Texas Biotechnology Corporation Cyclic peptide surface feature mimics of endothelin
US5744123A (en) * 1991-12-12 1998-04-28 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
US5916540A (en) 1994-10-24 1999-06-29 Glaxo Group Limited Aerosol formulations containing P134A and/or P227 and particulate medicament
US5653962A (en) * 1991-12-12 1997-08-05 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
US5658549A (en) * 1991-12-12 1997-08-19 Glaxo Group Limited Aerosol formulations containing propellant 134a and fluticasone propionate
IL104068A (en) 1991-12-12 1998-10-30 Glaxo Group Ltd Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant
CA2125666C (en) 1991-12-12 2002-07-16 Rachel Ann Akehurst Medicaments
US5674471A (en) * 1991-12-12 1997-10-07 Glaxo Group Limited Aerosol formulations containing P134a and salbutamol
US5736124A (en) * 1991-12-12 1998-04-07 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
US7101534B1 (en) 1991-12-18 2006-09-05 3M Innovative Properties Company Suspension aerosol formulations
US5301664A (en) * 1992-03-06 1994-04-12 Sievers Robert E Methods and apparatus for drug delivery using supercritical solutions
ES2177544T3 (es) * 1992-06-12 2002-12-16 Teijin Ltd Polvo ultrafinno para inhalar y metodo para su preparacion.
MX9304585A (es) 1992-07-31 1994-03-31 Glaxo Group Ltd Formulacion farmaceutica en aerosol, lata adecuada para liberar la formulacion e inhalador de dosis dosificada que comprende la lata.
WO1994022427A1 (en) * 1993-04-01 1994-10-13 Amgen Inc. Method for preparing drugs to treat dermal disorders
US6613804B2 (en) 1993-05-20 2003-09-02 Encysive Pharmaceuticals, Inc. Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
US6030991A (en) * 1993-05-20 2000-02-29 Texas Biotechnology Corp. Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US6342610B2 (en) 1993-05-20 2002-01-29 Texas Biotechnology Corp. N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US6376523B1 (en) 1994-05-20 2002-04-23 Texas Biotechnology Corporation Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US6541498B2 (en) 1993-05-20 2003-04-01 Texas Biotechnology Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US6551618B2 (en) 1994-03-15 2003-04-22 University Of Birmingham Compositions and methods for delivery of agents for neuronal regeneration and survival
EP0774956A1 (de) * 1994-08-09 1997-05-28 Schering Corporation Herstellungsverfahren für beclommethasondiprppionat-freon-klathrat
US5980949A (en) * 1994-10-03 1999-11-09 Astra Aktiebolag Formulation for inhalation
US5983956A (en) * 1994-10-03 1999-11-16 Astra Aktiebolag Formulation for inhalation
US5804560A (en) * 1995-01-06 1998-09-08 Sibia Neurosciences, Inc. Peptide and peptide analog protease inhibitors
US6017887A (en) * 1995-01-06 2000-01-25 Sibia Neurosciences, Inc. Peptide, peptide analog and amino acid analog protease inhibitors
US5646130A (en) * 1995-06-30 1997-07-08 Ocean University Of Oingdao Low molecular weight sulfated polysaccharides and uses thereof
US5977117A (en) * 1996-01-05 1999-11-02 Texas Biotechnology Corporation Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin
US5700487A (en) * 1996-03-04 1997-12-23 The Ohio State University Treatment of pulmonary inflammation
US5958905A (en) 1996-03-26 1999-09-28 Texas Biotechnology Corporation Phosphoramidates, phosphinic amides and related compounds and the use thereof to modulate the activity of endothelin
US5804585A (en) * 1996-04-15 1998-09-08 Texas Biotechnology Corporation Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin
AU736301B2 (en) * 1996-05-01 2001-07-26 Imarx Therapeutics, Inc. Methods for delivering compounds into a cell
US6416960B1 (en) 1996-08-08 2002-07-09 Prolume, Ltd. Detection and visualization of neoplastic tissues and other tissues
US6380222B2 (en) 1996-10-11 2002-04-30 Astrazeneca Ab Use of an H+, K+-atpase inhibitor in the treatment of nasal polyps
SE9603725D0 (sv) * 1996-10-11 1996-10-11 Astra Ab New teatment
WO1998026277A2 (en) 1996-12-12 1998-06-18 Prolume, Ltd. Apparatus and method for detecting and identifying infectious agents
SE9700133D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
HU227183B1 (en) 1997-04-28 2010-09-28 Encysive Pharmaceuticals Inc Sulfonamide derivatives and pharmaceutical compositions containing them for the treatment of endothelin-mediated disorders
US5783705A (en) 1997-04-28 1998-07-21 Texas Biotechnology Corporation Process of preparing alkali metal salys of hydrophobic sulfonamides
US6342611B1 (en) * 1997-10-10 2002-01-29 Cytovia, Inc. Fluorogenic or fluorescent reporter molecules and their applications for whole-cell fluorescence screening assays for capsases and other enzymes and the use thereof
US6362009B1 (en) 1997-11-21 2002-03-26 Merck & Co., Inc. Solid phase synthesis of heterocycles
EP1054694A2 (de) 1998-02-13 2000-11-29 Selective Genetics, Inc. Gleichzeitige strömungsdurchmischung zur herstellung von zusammensetzungen, die gentherapievektoren enthalten
EP1925320A3 (de) 1998-03-27 2008-09-03 Prolume, Ltd. Luciferasen, fluoreszierende Proteine, Nukleinsäuren zur Kodierung der Luciferasen und der fluoreszierenden Proteine sowie deren Verwendung zur Diagnose, zum Screening mit hohem Durchsatz und zur Behandlung neuartiger Probleme
ATE276754T1 (de) * 1998-07-21 2004-10-15 Cytovia Inc Neue fluoreszensfarbstoffe und ihre anwendung in fluoreszensnachweisverfahren ganzer zellen für kaspasen, peptidasen, proteasen und andere enzyme sowie deren verwendung
US6667299B1 (en) * 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
US6638977B1 (en) 1999-11-19 2003-10-28 Corvas International, Inc. Plasminogen activator inhibitor antagonists
WO2001036351A2 (en) 1999-11-19 2001-05-25 Corvas International, Inc. Plasminogen activator inhibitor antagonists related applications
US7897140B2 (en) 1999-12-23 2011-03-01 Health Research, Inc. Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents
SK9532002A3 (en) 1999-12-31 2003-06-03 Texas Biotechnology Corp Sulfonamides and derivatives thereof that modulate the activity of endothelin
US7109315B2 (en) 2000-03-15 2006-09-19 Bruce J. Bryan Renilla reniformis fluorescent proteins, nucleic acids encoding the fluorescent proteins and the use thereof in diagnostics, high throughput screening and novelty items
US6544497B2 (en) 2001-02-15 2003-04-08 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
US6596262B2 (en) 2001-02-15 2003-07-22 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
US6485707B2 (en) 2001-02-15 2002-11-26 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
US20030129203A1 (en) * 2001-08-27 2003-07-10 Nautilus Biotech S.A. Mutant recombinant adeno-associated viruses
US20050065118A1 (en) * 2001-10-16 2005-03-24 Jing Wang Organosulfur inhibitors of tyrosine phosphatases
AUPR868201A0 (en) * 2001-11-05 2001-11-29 Thorlock International Limited Q-factor switching method and apparatus for detecting nuclear quadrupole and nuclear magnetic resonance signals
WO2003060078A2 (en) * 2001-12-21 2003-07-24 X-Ceptor Therapeutics, Inc. Heterocyclic modulators of nuclear receptors
EP1465869B1 (de) 2001-12-21 2013-05-15 Exelixis Patent Company LLC Modulatoren von lxr
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
US20030199594A1 (en) * 2002-04-23 2003-10-23 Rasik Shah Helium propellant composition for use with aerosols
US20040001801A1 (en) * 2002-05-23 2004-01-01 Corvas International, Inc. Conjugates activated by cell surface proteases and therapeutic uses thereof
AU2003248747A1 (en) 2002-06-27 2004-01-19 Health Research, Inc. Fluorinated chlorin and bacteriochlorin photosensitizers for photodynamic therapy
US7053210B2 (en) 2002-07-02 2006-05-30 Health Research, Inc. Efficient synthesis of pyropheophorbide a and its derivatives
US20060020396A1 (en) * 2002-09-09 2006-01-26 Rene Gantier Rational directed protein evolution using two-dimensional rational mutagenesis scanning
US20050202438A1 (en) * 2002-09-09 2005-09-15 Rene Gantier Rational directed protein evolution using two-dimensional rational mutagenesis scanning
ES2343518T3 (es) * 2002-09-09 2010-08-03 Hanall Biopharma Co., Ltd. Polipeptidos interferon alfa modificados resistentes a proteasas.
CA2506415A1 (en) 2002-11-19 2004-06-03 Achillion Pharmaceuticals, Inc. Substituted aryl thioureas and releated compounds; inhibitors of viral replication
JP2006511297A (ja) * 2002-12-18 2006-04-06 グラクソ　グループ　リミテッド ベント型マウスピースを有する投薬システム
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
MXPA05009429A (es) 2003-03-05 2005-12-12 Halozyme Inc Glicoproteina hialuronidasa soluble (shasegp), proceso para preparar la misma, usos y composiciones farmaceuticas que la comprenden.
US7871607B2 (en) * 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
CN102584813B (zh) * 2003-05-14 2016-07-06 Ngc药物公司 化合物及其在调节淀粉样蛋白β中的用途
WO2005000298A2 (en) * 2003-06-03 2005-01-06 Novartis Ag 5-membered heterocycle-based p-38 inhibitors
EP1911754B1 (de) 2003-08-13 2013-10-09 Takeda Pharmaceutical Company Limited Dipeptidyl-Peptidase-Hemmer
US7420000B2 (en) 2003-09-10 2008-09-02 University Of Southern California Amino phosphonate and amino bis-phosphonate derivatives
US20050148534A1 (en) * 2003-09-22 2005-07-07 Castellino Angelo J. Small molecule compositions and methods for increasing drug efficiency using compositions thereof
WO2005090370A1 (en) * 2004-02-05 2005-09-29 The Regents Of The University Of California Pharmacologically active agents containing esterified phosphonates and methods for use thereof
US8519158B2 (en) 2004-03-12 2013-08-27 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
MXPA06013381A (es) 2004-05-20 2007-03-01 Scripps Research Inst Estabilizacion de transtiretina.
JP2008503490A (ja) * 2004-06-17 2008-02-07 センジェント・セラピューティクス・インコーポレイテッド チロシンホスファターゼの三置換窒素調節物質
EP1786421A2 (de) * 2004-07-09 2007-05-23 Cengent Therapeutics, Inc. Sauerstoff/stickstoff-heterozyklus-hemmer von tyrosinphosphatasen
WO2006017295A2 (en) 2004-07-12 2006-02-16 Idun Pharmaceuticals, Inc. Tetrapeptide analogs
EP1841749A1 (de) 2004-09-02 2007-10-10 Metabasis Therapeutics, Inc. Thiazol- und thiadiazolderivate als inhibitoren von tyrosinphosphatasen
NZ588432A (en) 2004-09-17 2012-03-30 Whitehead Biomedical Inst Compounds, Compositions and Methods of Inhibiting Alpha-Synuclein Toxicity
US7998930B2 (en) 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
EP1828192B1 (de) 2004-12-21 2014-12-03 Takeda Pharmaceutical Company Limited Dipeptidylpeptidasehemmer
CN101189249B (zh) 2005-04-01 2013-04-17 加利福尼亚大学董事会 膦酰基-戊-2-烯-1-基核苷和类似物
US20060251619A1 (en) * 2005-05-04 2006-11-09 Gilles Borrelly Modified interferon-gamma polypeptides and methods for using modified interferon-gamma polypeptides
BRPI0609191B8 (pt) 2005-06-17 2021-05-25 Ligand Pharm Inc métodos e compostos moduladores de receptor de androgênio
WO2007002109A2 (en) * 2005-06-20 2007-01-04 The Regents Of The University Of California Multidentate pyrone-derived chelators for medicinal imaging and chelation
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
US8492428B2 (en) * 2005-09-20 2013-07-23 Mayo Foundation For Medical Education And Research Small-molecule botulinum toxin inhibitors
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
US20070093443A1 (en) 2005-10-21 2007-04-26 Madison Edwin L Modified proteases that inhibit complement activation
US8138361B2 (en) * 2005-12-28 2012-03-20 The Trustees Of The University Of Pennsylvania C-10 carbamates of taxanes
US8063221B2 (en) * 2006-03-13 2011-11-22 Kyorin Pharmaceutical Co., Ltd. Aminoquinolones as GSK-3 inhibitors
US20080003202A1 (en) * 2006-03-28 2008-01-03 Thierry Guyon Modified interferon-beta (IFN-beta) polypeptides
CN101460161A (zh) * 2006-03-29 2009-06-17 弗尔德里克斯制药股份有限公司 α-突触核蛋白毒性的抑制
US20070286814A1 (en) * 2006-06-12 2007-12-13 Medispray Laboratories Pvt. Ltd. Stable aerosol pharmaceutical formulations
EP2423307A1 (de) 2006-06-19 2012-02-29 Catalyst Biosciences, Inc. Modifizierte Gerinnungsfaktor-IV-Polypeptide und deren Verwendung bei der Behandlung
SG170032A1 (en) 2006-08-28 2011-04-29 Kyowa Hakko Kirin Co Ltd Antagonistic human light-specific human monoclonal antibodies
WO2008036379A2 (en) 2006-09-21 2008-03-27 Activx Biosciences, Inc. Serine hydrolase inhibitors
AU2007313961A1 (en) 2006-10-09 2008-05-08 Takeda Pharmaceutical Company Limited Kinase inhibitors
JP2010505961A (ja) 2006-10-09 2010-02-25 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
WO2008055236A2 (en) 2006-10-31 2008-05-08 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors
US20100137421A1 (en) * 2006-11-08 2010-06-03 Emmanuel Theodorakis Small molecule therapeutics, synthesis of analogues and derivatives and methods of use
EP2120998B1 (de) 2006-11-28 2013-08-07 HanAll Biopharma Co., Ltd. Modifizierte erythropoetin-polypeptide und ihre verwendungen zur behandlung
WO2009070164A1 (en) 2007-11-28 2009-06-04 University Of Central Florida Vigor enhancement via administration of pyrimidine derivatives
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
AU2007338689A1 (en) * 2006-12-22 2008-07-03 Encysive Pharmaceuticals, Inc. Modulators of C3a receptor and methods of use thereof
JP5825757B2 (ja) 2007-02-11 2015-12-02 マップ・ファーマシューティカルズ・インコーポレイテッド 副作用プロファイルを最小限にしながら片頭痛の迅速な緩和を可能にするｄｈｅの治療上の投与方法
DK2144604T3 (da) * 2007-02-28 2011-10-17 Conatus Pharmaceuticals Inc Fremgangsmåder til behandling af kronisk viral hepatitis C under anvendelse af RO 113-0830
CA2699151A1 (en) * 2007-09-11 2009-03-19 Activx Biosciences, Inc. Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors
EP2203459B1 (de) 2007-09-12 2016-03-16 Kyorin Pharmaceutical Co., Ltd. Spirocyclische aminochinolone als gsk-3-inhibitoren
CA2699607A1 (en) 2007-09-25 2009-04-02 Takeda Pharmaceutical Company Limited Polo-like kinase inhibitors
US20090264421A1 (en) * 2007-10-05 2009-10-22 Bible Keith C Methods and Compositions for Treating Cancer
CN101917845A (zh) 2007-11-21 2010-12-15 法马克西斯制药公司 Ssao/vap-1的卤代烯丙胺抑制剂及其用途
DK2222636T3 (da) 2007-12-21 2013-06-03 Ligand Pharm Inc Selektive androgenreceptormodulatorer (SARMS) og anvendelser deraf
TWI395593B (zh) 2008-03-06 2013-05-11 Halozyme Inc 可活化的基質降解酵素之活體內暫時性控制
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
KR20160052812A (ko) 2008-04-14 2016-05-12 할로자임, 아이엔씨 히알루로난 관련 질환 및 상태 치료용 변형된 히알루로니다제 및 그 용도
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
JP2011525535A (ja) 2008-06-24 2011-09-22 武田薬品工業株式会社 ＰＩ３Ｋ／ｍＴＯＲ阻害剤
PL2318035T3 (pl) 2008-07-01 2019-10-31 Curemark Llc Sposoby i kompozycje do leczenia objawów zaburzeń neurologicznych i zaburzeń zdrowia psychicznego
CN103205407B (zh) 2008-12-09 2016-03-16 哈洛齐梅公司 延长的可溶性ph20多肽及其用途
ES2668909T3 (es) 2009-01-06 2018-05-23 Galenagen, Llc Composiciones que comprenden proteasa, amilasa y lipasa para su uso en el tratamiento de infecciones por Staphylococcus aureus
NZ593823A (en) 2009-01-06 2013-09-27 Curelon Llc Compositions and methods for the treatment or the prevention of infections by e. coli
EP2403523A1 (de) 2009-03-06 2012-01-11 Halozyme, Inc. Temperaturempfindliche mutanten von matrix metalloprotease 1 und ihre verwendungen
MX2011009414A (es) * 2009-03-11 2011-10-19 Kyorin Seiyaku Kk 7-cicloalquiloaminoquinolonas como inhibidores de gsk-3.
JP5730281B2 (ja) 2009-03-27 2015-06-10 武田薬品工業株式会社 ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
JP5715625B2 (ja) 2009-07-30 2015-05-07 武田薬品工業株式会社 ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤
US8404728B2 (en) 2009-07-30 2013-03-26 Mayo Foundation For Medical Education And Research Small-molecule botulinum toxin inhibitors
WO2011041293A1 (en) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
WO2011057214A2 (en) 2009-11-09 2011-05-12 Neurogenetic Pharmaceuticals, Inc. Gamma-secretase modulatory compounds, methods for identifying same, and uses therefor
US20110301235A1 (en) 2009-12-02 2011-12-08 Alquest Therapeutics, Inc. Organoselenium compounds and uses thereof
SG181896A1 (en) * 2009-12-23 2012-07-30 Map Pharmaceuticals Inc Novel ergoline analogs
EP2521721B1 (de) 2009-12-30 2014-10-01 Shanghai Fochon Pharmaceutical Co. Ltd 3-(3-aminopiperidin-1-yl)-5-oxo-1,2,4-triazin-derivate als dipeptidyl-peptidase iv (dpp iv)-hemmer
RS53176B (en) 2010-02-03 2014-06-30 Takeda Pharmaceutical Company Limited KINASE INHIBITORS 1 REGULATING SIGNALS IN APOPTOSIS
JP6069661B2 (ja) 2010-06-24 2017-02-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 種々のアミロイドβペプチドアロフォームレベルの調節における組成物及びその使用
MX362974B (es) 2011-04-21 2019-02-28 Curemark Llc Compuestos para el tratamiento de alteraciones neuropsiquiatricas.
CA2838991A1 (en) 2011-06-23 2012-12-27 Map Pharmaceuticals, Inc. Novel fluoroergoline analogs
WO2013037482A1 (en) 2011-09-15 2013-03-21 Phenex Pharmaceuticals Ag Farnesoid x receptor agonists for cancer treatment and prevention
CA2859173A1 (en) 2011-12-19 2013-06-27 Map Pharmaceuticals, Inc. Novel iso-ergoline derivatives
SG10201506202RA (en) 2011-12-21 2015-09-29 Map Pharmaceuticals Inc Novel neuromodulatory compounds
ES2749620T3 (es) 2011-12-30 2020-03-23 Halozyme Inc Variantes de polipéptidos de PH20, formulaciones y usos de los mismos
WO2013134047A2 (en) 2012-03-07 2013-09-12 The Mclean Hospital Corporation Aminoquinoline derivatives and uses thereof
SI2833905T1 (en) 2012-04-04 2018-08-31 Halozyme, Inc. Combination therapy with hyaluronidase and tumane-directed taxane
RS57086B1 (sr) 2012-05-02 2018-06-29 Boehringer Ingelheim Int Supstituisani 3-haloalilamin inhibitori ssao i njihova primena
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
EP2861562B1 (de) 2012-06-14 2018-05-09 Mayo Foundation For Medical Education And Research Pyrazolderivate als hemmer von stat3
US9012640B2 (en) 2012-06-22 2015-04-21 Map Pharmaceuticals, Inc. Cabergoline derivatives
US9074186B2 (en) 2012-08-15 2015-07-07 Boston Medical Center Corporation Production of red blood cells and platelets from stem cells
EP2934143A4 (de) 2012-12-21 2016-06-15 Map Pharmaceuticals Inc Neuartige methysergidderivate
WO2014107745A1 (en) 2013-01-07 2014-07-10 Halozyme, Inc. Metal sensitive mutants of matrix metalloproteases and uses thereof
JP6490597B2 (ja) 2013-02-22 2019-03-27 ユニヴァーシティー オブ サザン カリフォルニア 眼の疾患および障害を治療するための方法
EP2968296B1 (de) 2013-03-12 2020-09-02 The Regents of the University of California Gammasekretasemodulatoren
NZ712479A (en) 2013-03-15 2019-01-25 Univ Southern California Methods, compounds, and compositions for the treatment of angiotensin-related diseases
NZ714765A (en) 2013-06-06 2021-12-24 Pf Medicament Anti-c10orf54 antibodies and uses thereof
TW201534726A (zh) 2013-07-03 2015-09-16 Halozyme Inc 熱穩定ｐｈ２０玻尿酸酶變異體及其用途
EP3613418A1 (de) 2014-01-17 2020-02-26 Ligand Pharmaceuticals, Inc. Verfahren und zusammensetzungen zur modulierung von hormonspiegeln
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
CN106470679A (zh) 2014-05-12 2017-03-01 科内图斯医药公司 用半胱天冬酶抑制剂治疗慢性肝脏疾病并发症
RS61678B1 (sr) 2014-05-28 2021-05-31 Agenus Inc Anti-gitr antitela i postupci za njihovu primenu
US9499514B2 (en) 2014-07-11 2016-11-22 Celgene Corporation Antiproliferative compounds and methods of use thereof
CA2964317C (en) 2014-10-14 2021-10-05 Halozyme, Inc. Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
EP3209658A1 (de) 2014-10-24 2017-08-30 Biogen MA Inc. Diterpenoidderivate und verfahren zur verwendung
WO2016070107A1 (en) 2014-10-31 2016-05-06 The General Hospital Corporation Potent gamma-secretase modulators
KR20240123432A (ko) 2014-12-11 2024-08-13 피에르 파브르 메디카먼트 항-c10orf54 항체들 및 그들의 용도들
EP3237450B1 (de) 2014-12-22 2021-03-03 The Rockefeller University Anti-mertk-antikörper und verwendungen davon
US9657020B2 (en) 2015-01-20 2017-05-23 Xoc Pharmaceuticals, Inc. Ergoline compounds and uses thereof
MX2017009406A (es) 2015-01-20 2018-01-18 Xoc Pharmaceuticals Inc Compuestos de tipo isoergolina y usos de estos.
LT3265123T (lt) 2015-03-03 2023-01-25 Kymab Limited Antikūnai, naudojimas ir būdai
WO2016176617A2 (en) 2015-04-29 2016-11-03 New York University Method for treating high-grade gliomas
WO2016196237A1 (en) 2015-05-29 2016-12-08 Agenus Inc. Anti-ctla-4 antibodies and methods of use thereof
ES2787073T3 (es) 2015-08-17 2020-10-14 Kura Oncology Inc Métodos para tratar pacientes con cáncer con inhibidores de la farnesiltransferasa
SG10201913276WA (en) 2015-09-01 2020-02-27 Agenus Inc Anti-pd-1 antibodies and methods of use thereof
WO2017079566A1 (en) 2015-11-05 2017-05-11 Conatus Pharmaceuticals, Inc. Caspase inhibitors for use in the treatment of liver cancer
EP4455145A2 (de) 2015-12-02 2024-10-30 Astraea Therapeutics, LLC Piperidinyl-nociceptin-rezeptorverbindungen
US10112924B2 (en) 2015-12-02 2018-10-30 Astraea Therapeutics, Inc. Piperdinyl nociceptin receptor compounds
AU2016381974A1 (en) 2015-12-31 2018-07-12 Conatus Pharmaceuticals Inc. Methods of using caspase inhibitors in treatment of liver disease
CN108712904B (zh) 2016-01-08 2022-08-02 细胞基因公司 2-(4-氯苯基)-n-((2-(2,6-二氧代哌啶-3-基)-1-氧代异吲哚啉-5-基)甲基)-2,2-二氟乙酰胺的固体形式以及其药物组合物和用途
JP6956725B2 (ja) 2016-01-08 2021-11-02 セルジーン コーポレイション 抗増殖化合物、ならびにそれらの薬学的組成物及び使用
JP6880037B2 (ja) 2016-01-08 2021-06-02 セルジーン コーポレイション がんの治療方法と、治療法に対する臨床的感度の予測因子としてのバイオマーカーの使用
US10960013B2 (en) 2016-03-04 2021-03-30 East Carolina University J-series prostaglandin-ethanolamides as novel therapeutics for skin and/or oral disorders
EP3426352A4 (de) 2016-03-08 2019-11-13 Los Gatos Pharmaceuticals, Inc. Camptothecin-derivate und verwendungen davon
EP3426301A4 (de) 2016-03-08 2019-11-06 Los Gatos Pharmaceuticals, Inc. Verbundnanopartikel und verwendungen davon
WO2017180794A1 (en) 2016-04-13 2017-10-19 Skyline Antiinfectives, Inc. Deuterated o-sulfated beta-lactam hydroxamic acids and deuterated n-sulfated beta-lactams
WO2017184968A1 (en) 2016-04-22 2017-10-26 Kura Oncology, Inc. Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors
EP4190357A1 (de) 2016-05-13 2023-06-07 Institut Pasteur Hemmung von beta-2-nikotin-acetylcholinrezeptoren zur behandlung von morbus-alzheimer-pathologie
KR20230091191A (ko) 2016-05-27 2023-06-22 아게누스 인코포레이티드 항-tim-3 항체 및 이의 사용 방법
MA45602A (fr) 2016-07-08 2019-05-15 Staten Biotechnology B V Anticorps anti-apoc3 et leurs méthodes d'utilisation
US10919904B2 (en) 2016-08-17 2021-02-16 North Carolina State University Northern-southern route to synthesis of bacteriochlorins
MX2019003683A (es) 2016-10-11 2019-08-22 Agenus Inc Anticuerpos anti gen 3 de activación linfocítica (lag 3 ) y métodos para usarlos.
EP3534947A1 (de) 2016-11-03 2019-09-11 Kymab Limited Antikörper, kombinationen mit antikörpern, biomarker, verwendungen und verfahren
HUE053927T2 (hu) 2016-11-03 2021-07-28 Kura Oncology Inc Farneziltranszferáz inhibitorok rák kezelésében történõ alkalmazásra
JP7045724B2 (ja) 2016-11-07 2022-04-01 ニューラクル サイエンス カンパニー リミテッド 配列類似性を持つ抗ファミリー１９、メンバーａ５抗体及びその用途
US10106521B2 (en) 2016-11-09 2018-10-23 Phloronol, Inc. Eckol derivatives, methods of synthesis and uses thereof
US10836774B2 (en) 2016-11-30 2020-11-17 North Carolina State University Methods for making bacteriochlorin macrocycles comprising an annulated isocyclic ring and related compounds
CN118634323A (zh) 2016-12-07 2024-09-13 艾吉纳斯公司 抗体和其使用方法
EP4289484A3 (de) 2016-12-07 2024-03-06 Agenus Inc. Anti-ctla-4-antikörper und verfahren zur verwendung davon
ES2892157T3 (es) 2017-02-21 2022-02-02 Kura Oncology Inc Métodos de tratamiento del cáncer con inhibidores de farnesil transferasa
US9956215B1 (en) 2017-02-21 2018-05-01 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
MX2019012223A (es) 2017-04-13 2019-12-09 Agenus Inc Anticuerpos anti-cd137 y metodos de uso de los mismos.
KR20190141659A (ko) 2017-04-21 2019-12-24 스태튼 바이오테크놀로지 비.브이. 항-apoc3 항체 및 이의 사용 방법
RS64576B1 (sr) 2017-05-01 2023-10-31 Agenus Inc Anti-tigit antitela i postupci njihove primene
US10085999B1 (en) 2017-05-10 2018-10-02 Arixa Pharmaceuticals, Inc. Beta-lactamase inhibitors and uses thereof
WO2018223065A1 (en) 2017-06-01 2018-12-06 Xoc Pharmaceuticals, Inc. Ergoline derivatives for use in medicine
EP3641801A1 (de) 2017-06-22 2020-04-29 Catalyst Biosciences, Inc. Modifizierte membrantyp-serinprotease 1 (mtsp-1)-polypeptide und verwendungsverfahren
CA3067681A1 (en) 2017-06-26 2019-01-03 Institut Pasteur Treatments to eliminate hiv reservoirs and reduce viral load
US11618783B2 (en) 2017-06-27 2023-04-04 Neuracle Science Co., Ltd. Anti-FAM19A5 antibodies and uses thereof
EP3645039A4 (de) 2017-06-27 2021-05-05 Neuracle Science Co., Ltd Verwendung von anti-fam19a5-antikörpern zur behandlung von fibrose
KR102511122B1 (ko) 2017-06-27 2023-03-22 주식회사 뉴라클사이언스 녹내장의 치료를 위한 항-서열 유사성 19를 가진 패밀리, 멤버 a5 항체의 용도
US11560425B2 (en) 2017-06-27 2023-01-24 Neuracle Science Co., Ltd. Use of anti-FAM19A5 antibodies for treating cancers
US11168326B2 (en) 2017-07-11 2021-11-09 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
US10806730B2 (en) 2017-08-07 2020-10-20 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
CA3071854A1 (en) 2017-08-07 2019-02-14 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
WO2019046556A1 (en) 2017-09-01 2019-03-07 East Carolina University COMPOUNDS, COMPOSITIONS, KITS AND METHODS FOR ACTIVATING IMMUNE CELLS AND / OR AN IMMUNE SYSTEM RESPONSE
EP3692171A4 (de) 2017-10-02 2021-06-23 Neuracle Science Co., Ltd Verwendung einer anti-familie mit sequenzähnlichkeit 19, element-a5-antikörper zur behandlung und diagnose von gemütsstörungen
CN111315772A (zh) 2017-10-31 2020-06-19 斯塔顿生物技术有限公司 抗apoc3抗体及其使用方法
WO2019099353A1 (en) 2017-11-15 2019-05-23 California State University Northridge Compositions and methods for the treatment and prevention of cancer
WO2019113269A1 (en) 2017-12-08 2019-06-13 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors
CN112424223A (zh) 2018-04-24 2021-02-26 纽洛可科学有限公司 抗序列相似家族19成员a5的抗体在治疗神经性疼痛中的用途
AU2019265888A1 (en) 2018-05-10 2020-11-26 Neuracle Science Co., Ltd. Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof
US20190351031A1 (en) 2018-05-16 2019-11-21 Halozyme, Inc. Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
CA3105352A1 (en) 2018-06-29 2020-01-02 Histogen, Inc. (s)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating cardiovascular diseases
CA3176812A1 (en) 2018-07-11 2020-01-16 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
CA3106418A1 (en) 2018-07-20 2020-01-23 Pierre Fabre Medicament Receptor for vista
US11242528B2 (en) 2018-08-28 2022-02-08 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
WO2020070678A2 (en) 2018-10-03 2020-04-09 Staten Biotechnology B.V. Antibodies specific for human and cynomolgus apoc3 and methods of use thereof
EP3873469A2 (de) 2018-11-01 2021-09-08 Kura Oncology, Inc. Verfahren zur behandlung von krebs mit farnesyltransferase-inhibitoren
EP3880231A1 (de) 2018-11-16 2021-09-22 NeoImmuneTech, Inc. Verfahren zur behandlung eines tumors mit einer kombination aus il-7-protein und einem immunprüfpunktinhibitor
WO2020132071A1 (en) 2018-12-19 2020-06-25 Shy Therapeutics. Llc Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and f1brotic disease
WO2020128033A1 (en) 2018-12-20 2020-06-25 Institut Pasteur Cellular metabolism of hiv-1 reservoir seeding in cd4+ t cells
TW202038953A (zh) 2018-12-21 2020-11-01 美商庫拉腫瘤技術股份有限公司 鱗狀細胞癌之治療
JP2022516725A (ja) 2018-12-28 2022-03-02 カタリスト・バイオサイエンシーズ・インコーポレイテッド 改変ウロキナーゼ型プラスミノゲンアクティベータポリペプチドおよび使用方法
US11613744B2 (en) 2018-12-28 2023-03-28 Vertex Pharmaceuticals Incorporated Modified urokinase-type plasminogen activator polypeptides and methods of use
TWI839461B (zh) 2019-02-06 2024-04-21 美商戴斯阿爾法股份有限公司 Il-17a調節物及其用途
CA3130303A1 (en) 2019-02-26 2020-09-03 Rgenix, Inc. High-affinity anti-mertk antibodies and uses thereof
JP2022524951A (ja) 2019-02-27 2022-05-11 アクティム・セラピューティクス・インコーポレイテッド 腫瘍、腫瘍常在免疫細胞および腫瘍微小環境にコロニー形成するよう操作した免疫刺激性細菌
US12024709B2 (en) 2019-02-27 2024-07-02 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
WO2020180663A1 (en) 2019-03-01 2020-09-10 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
BR112021017710A2 (pt) 2019-03-07 2021-11-16 Conatus Pharmaceuticals Inc Composto, composição farmacêutica, método de tratamento
TW202108170A (zh) 2019-03-15 2021-03-01 美商庫拉腫瘤技術股份有限公司 以法呢基轉移酶(farnesyltransferase)抑制劑治療癌症患者之方法
SG11202110472WA (en) 2019-03-29 2021-10-28 Kura Oncology Inc Methods of treating squamous cell carcinomas with farnesyltransferase inhibitors
US20220168296A1 (en) 2019-04-01 2022-06-02 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
WO2020223583A1 (en) 2019-05-02 2020-11-05 Kura Oncology, Inc. Methods of treating acute myeloid leukemia with farnesyltransferase inhibitors
WO2020236818A1 (en) 2019-05-20 2020-11-26 Nirvana Sciences Inc. Narrow emission dyes, compositions comprising same, and methods for making and using same
KR20220053007A (ko) 2019-08-30 2022-04-28 아게누스 인코포레이티드 항-cd96 항체 및 이의 사용 방법
MX2022003166A (es) 2019-09-16 2022-06-29 Dice Alpha Inc Moduladores de il-17a y usos de los mismos.
MX2022005705A (es) 2019-11-12 2022-08-16 Actym Therapeutics Inc Plataformas de suministro bacteriano inmunomoduladoras y su uso para el suministro de productos terapéuticos.
AU2021207586A1 (en) 2020-01-13 2022-07-21 Neoimmunetech, Inc. Method of treating a tumor with a combination of IL-7 protein and a bispecific antibody
AU2021217373A1 (en) 2020-02-05 2022-08-04 Neoimmunetech, Inc. Method of treating a solid tumor with a combination of an IL-7 protein and CAR-bearing immune cells
WO2021257828A1 (en) 2020-06-18 2021-12-23 Shy Therapeutics, Llc Substituted thienopyrimidines that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
JP2023532312A (ja) 2020-06-30 2023-07-27 プロセッタ バイオサイエンシズ， インク． イソキノリン誘導体、合成の方法及びそれらの使用
JP2023539454A (ja) 2020-08-12 2023-09-14 アクティム・セラピューティクス・インコーポレイテッド 免疫刺激細菌ベースのワクチン、治療薬およびｒｎａデリバリープラットフォーム
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
US20230398184A1 (en) 2020-10-26 2023-12-14 Neoimmunetech, Inc. Methods of inducing stem cell mobilization
US20240101629A1 (en) 2020-11-02 2024-03-28 Neoimmunetech, Inc. Use of interleukin-7 for the treatment of coronavirus
JP2023549112A (ja) 2020-11-05 2023-11-22 ネオイミューンテック， インコーポレイテッド Ｉｌ－７タンパク質とヌクレオチドワクチンの組み合わせで腫瘍を治療する方法
WO2022165000A1 (en) 2021-01-27 2022-08-04 Shy Therapeutics, Llc Methods for the treatment of fibrotic disease
US20240124483A1 (en) 2021-01-27 2024-04-18 Shy Therapeutics, Llc Methods for the Treatment of Fibrotic Disease
CA3211505A1 (en) 2021-03-10 2022-09-15 Lalit Kumar Sharma Alpha v beta 6 and alpha v beta 1 integrin inhibitors and uses thereof
WO2022226166A1 (en) 2021-04-22 2022-10-27 Protego Biopharma, Inc. Spirocyclic imidazolidinones and imidazolidinediones for treatment of light chain amyloidosis
EP4347568A1 (de) 2021-05-27 2024-04-10 Protego Biopharma, Inc. Heteroaryldiamid-ire1/xbp1s-aktivatoren
IL309349A (en) 2021-06-14 2024-02-01 argenx BV Antibodies against interleukin 9 and methods of using them
EP4402124A1 (de) 2021-10-22 2024-07-24 Prosetta Biosciences, Inc. Neue wirtsgerichtete pan-respiratorische antivirale kleinmolekül-therapeutika
CA3237696A1 (en) 2021-11-08 2023-05-11 Progentos Therapeutics, Inc. Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
EP4456907A1 (de) 2021-12-30 2024-11-06 NeoImmuneTech, Inc. Verfahren zur behandlung eines tumors mit einer kombination aus il-7-protein und vegf-antagonist
WO2023129576A2 (en) 2022-01-03 2023-07-06 Lilac Therapeutics, Inc. Acyclic thiol prodrugs
US11932665B2 (en) 2022-01-03 2024-03-19 Lilac Therapeutics, Inc. Cyclic thiol prodrugs
GB2619907A (en) 2022-04-01 2023-12-27 Kanna Health Ltd Novel crystalline salt forms of mesembrine
US20230331693A1 (en) 2022-04-14 2023-10-19 Bristol-Myers Squibb Company Gspt1 compounds and methods of use of the novel compounds
WO2023198757A1 (en) 2022-04-14 2023-10-19 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Alpha-1-antitrypsin for treating paramyxoviridae or orthomyxoviridae infections
US20240209100A1 (en) 2022-10-21 2024-06-27 Diagonal Therapeutics Inc. Heteromeric agonistic antibodies to il-18 receptor
US20240174695A1 (en) 2022-10-26 2024-05-30 Protego Biopharma, Inc. Spirocycle Containing Bicyclic Heteroaryl Compounds
WO2024092037A1 (en) 2022-10-26 2024-05-02 Protego Biopharma, Inc. Spirocycle containing pyridone compounds
US20240174673A1 (en) 2022-10-26 2024-05-30 Protego Biopharma, Inc. Spirocycle Containing Pyridine Compounds
WO2024102722A1 (en) 2022-11-07 2024-05-16 Neoimmunetech, Inc. Methods of treating a tumor with an unmethylated mgmt promoter
WO2024118801A1 (en) 2022-11-30 2024-06-06 Protego Biopharma, Inc. Linear heteroaryl diamide ire1/xbp1s activators
WO2024118810A1 (en) 2022-11-30 2024-06-06 Protego Biopharma, Inc. Cyclic pyrazole diamide ire1/xbp1s activators
WO2024194686A2 (en) 2023-03-17 2024-09-26 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof
WO2024194685A2 (en) 2023-03-17 2024-09-26 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof
WO2024211796A1 (en) 2023-04-07 2024-10-10 Diagonal Therapeutics Inc. Bispecific agonistic antibodies to activin a receptor like type 1 (alk1)
WO2024211807A1 (en) 2023-04-07 2024-10-10 Diagonal Therapeutics Inc. Hinge-modified bispecific antibodies

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2849460A (en) * 1953-11-17 1958-08-26 Olin Mathieson Purification of steroids
BE556587A (de) * 1957-01-31 1957-04-11
GB1047518A (en) * 1963-06-11 1966-11-02 Glaxo Lab Ltd 17ª‡-monoesters of 11,17,21-trihydroxy steroid compounds
US3320125A (en) * 1964-04-28 1967-05-16 Merck & Co Inc Inhalation aerosol composition
US3282791A (en) * 1965-08-17 1966-11-01 Merck & Co Inc Inhalation aerosol suspension of anhydrous disodium dexamethasone phosphate, propellents, and sorbitan trioleate
NL6810103A (de) * 1967-07-31 1969-02-04
GB1253831A (en) * 1968-01-19 1971-11-17 Glaxo Lab Ltd 9alpha,21-DIHALOPREGNANE COMPOUNDS
US4119548A (en) * 1977-10-28 1978-10-10 Mobil Oil Corporation Reaction product of nickel thiobis(alkylphenolate) and thiobis(alkylphenol) and organic compositions containing the same

Also Published As

Publication number Publication date
AU471577B2 (en) 1976-04-29
DE2320111A1 (de) 1973-10-31
NL157797B (nl) 1978-09-15
PH13620A (en) 1980-08-07
LU67462A1 (de) 1973-07-05
US4414209A (en) 1983-11-08
US4364923A (en) 1982-12-21
GB1429184A (en) 1976-03-24
DK134923C (de) 1977-07-04
NL7305438A (de) 1973-10-23
CA994753A (en) 1976-08-10
FI53067B (de) 1977-10-31
IE37541B1 (en) 1977-08-17
JPS531814B2 (de) 1978-01-23
SE399642B (sv) 1978-02-27
ZA732713B (en) 1974-11-27
IL42038A0 (en) 1973-06-29
AU5466073A (en) 1974-10-24
DE2320111C2 (de) 1986-12-04
ES413911A1 (es) 1976-06-16
NO140303C (no) 1979-08-08
YU108673A (en) 1982-06-30
IL42038A (en) 1976-11-30
HU171209B (hu) 1977-12-28
BE798458A (fr) 1973-10-19
FI53067C (de) 1978-02-10
DK134923B (da) 1977-02-14
FR2182981A1 (de) 1973-12-14
FR2182981B1 (de) 1976-12-31
JPS4919014A (de) 1974-02-20
YU39602B (en) 1985-03-20
ATA352973A (de) 1978-06-15
AR196524A1 (es) 1974-02-06
IE37541L (en) 1973-10-20
NO140303B (no) 1979-04-30

Similar Documents

Publication Publication Date Title
AT348115B (de) Verfahren zur umwandlung eines anti- inflammatorisch wirkenden steroids
AT328630B (de) Verfahren zur herstellung neuer steroide
AT302530B (de) Verfahren zur Herstellung einer Salbenfolie
CH495968A (de) Verfahren zur Herstellung neuer Steroide
AT307344B (de) Verfahren zur Bodenprobenentnahme und Gerät zur Durchführung dieses Verfahrens
AT336811B (de) Verfahren zur herstellung von steroidspirolactonen
AT298698B (de) Verfahren zur Herstellung neuer Steroide
AT338201B (de) Verfahren zur gewinnung von neuer steroid-delta-isomerase
NL177327C (nl) Werkwijze ter bereiding van ergosterol of esters daarvan.
AT330967B (de) Verfahren zur herstellung neuer steroidverbindungen
AT314098B (de) Verfahren zur Äthinylierung von 17-Ketosteroiden
ATA436471A (de) Verfahren zur herstellung neuer steroide
AT315397B (de) Verfahren zur Herstellung neuer Steroide
AT330966B (de) Verfahren zur herstellung neuer steroide
ATA906971A (de) Verfahren zur herstellung neuer 3-oximino-17alfa-propadienyl-substituierter steroide
ATA135872A (de) Verfahren zur herstellung neuer steroide
AT359212B (de) Verfahren zur herstellung neuer pharma- zeutisch aktiver steroide
CH499511A (de) Verfahren zur Herstellung eines 9B,10a-Steroids
ATA312673A (de) Verfahren zur herstellung neuer steroide
ATA353071A (de) Verfahren zur herstellung neuer 17alpha-propadienylsubstituierter steroide
ATA353271A (de) Verfahren zur herstellung neuer substituierter steroide
AT329779B (de) Verfahren zur herstellung neuer steroiden
CH552579A (de) Verfahren zur herstellung neuer steroide.
CH553766A (de) Verfahren zur herstellung neuer steroide.
ATA353471A (de) Verfahren zur herstellung substituierter steroide

Legal Events

Date Code Title Description
ELJ Ceased due to non-payment of the annual fee
ELA Expired due to lapse of time